Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Virtual Multidisciplinary Tumor Boards: A Narrative Review Focused on Lung Cancer.
Gebbia V, Guarini A, Piazza D, Bertani A, Spada M, Verderame F, Sergi C, Potenza E, Fazio I, Blasi L, La Sala A, Mortillaro G, Roz E, Marchese R, Chiarenza M, Soto-Parra H, Valerio MR, Agneta G, Amato C, Lipari H, Baldari S, Ferraù F, Di Grazia A, Mancuso G, Rizzo S, Firenze A. Gebbia V, et al. Among authors: verderame f. Pulm Ther. 2021 Dec;7(2):295-308. doi: 10.1007/s41030-021-00163-8. Epub 2021 Jun 4. Pulm Ther. 2021. PMID: 34089169 Free PMC article. Review.
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
Vergote I, Scambia G, O'Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Raza Mirza M, Kroep JR, Ma H, Pickett CA, Monk BJ; TRINOVA-3/ENGOT-ov2/GOG-3001 investigators. Vergote I, et al. Lancet Oncol. 2019 Jun;20(6):862-876. doi: 10.1016/S1470-2045(19)30178-0. Epub 2019 May 7. Lancet Oncol. 2019. PMID: 31076365 Free article. Clinical Trial.
Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience.
Gebbia V, Del Prete S, Borsellino N, Ferraù F, Tralongo P, Verderame F, Leonardi V, Capasso E, Maiello E, Bordonaro R, Stinco S, Agostara B, Barone C. Gebbia V, et al. Among authors: verderame f. Clin Colorectal Cancer. 2006 Mar;5(6):422-8. doi: 10.3816/CCC.2006.n.013. Clin Colorectal Cancer. 2006. PMID: 16635281 Clinical Trial.
Vinorelbine and 5-fluorouracil bolus and/or continuous venous infusion plus levofolinic acid as second-line chemotherapy for metastatic breast cancer: an analysis of results in clinical practice of the Gruppo Oncologico Italia Meridionale (GOIM).
Gebbia V, Caruso M, Borsellino N, Ajello R, Tirrito ML, Chiarenza M, Valenza R, Verderame F, Varvara F, Marrazzo A, Bajardi E, Ferrao F, Bordonaro R, Tralongo P. Gebbia V, et al. Among authors: verderame f. Anticancer Res. 2006 Jul-Aug;26(4B):3143-50. Anticancer Res. 2006. PMID: 16886648 Free article.
Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
Gebbia V, Galetta D, Lorusso V, Caruso M, Verderame F, Pezzella G, Borsellino N, Durini E, Valenza R, Agostara B, Colucci G; Gruppo Oncologico Italia Meridionale. Gebbia V, et al. Among authors: verderame f. Lung Cancer. 2008 Sep;61(3):369-77. doi: 10.1016/j.lungcan.2008.01.010. Epub 2008 Mar 4. Lung Cancer. 2008. PMID: 18308419 Clinical Trial.
Cancer patient-centered home care: a new model for health care in oncology.
Tralongo P, Ferraù F, Borsellino N, Verderame F, Caruso M, Giuffrida D, Butera A, Gebbia V. Tralongo P, et al. Among authors: verderame f. Ther Clin Risk Manag. 2011;7:387-92. doi: 10.2147/TCRM.S22119. Epub 2011 Sep 9. Ther Clin Risk Manag. 2011. PMID: 21941445 Free PMC article.
Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?
Serretta V, Valerio MR, Costa R, Tripoli V, Murabito A, Princiotta A, Scalici Gesolfo C, Borsellino N, Verderame F, Gebbia V, Licari M, Sanfilippo C; members of the GSTU Foundation. Serretta V, et al. Among authors: verderame f. Urol Oncol. 2019 Dec;37(12):964-969. doi: 10.1016/j.urolonc.2019.08.009. Epub 2019 Oct 7. Urol Oncol. 2019. PMID: 31601517
Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study.
Adamo V, Ricciardi GRR, Giuffrida D, Scandurra G, Russo A, Blasi L, Spadaro P, Iacono C, Soto Parra HJ, Savarino A, Ferraú F, Zerilli F, Verderame F, Butera A, Santangelo C, Franchina V, Caruso M. Adamo V, et al. Among authors: verderame f. Ther Adv Med Oncol. 2019 Dec 19;11:1758835919895755. doi: 10.1177/1758835919895755. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31903098 Free PMC article.
Reactions and countermeasures of medical oncologists towards the incoming COVID-19 pandemic: a WhatsApp messenger-based report from the Italian College of Chief Medical Oncologists.
Blasi L, Bordonaro R, Borsellino N, Butera A, Caruso M, Cordio S, Liborio DC, Ferraù F, Giuffrida D, Parra HS, Spada M, Tralongo P, Valenza R, Verderame F, Vitello S, Zerilli F, Piazza D, Firenze A, Gebbia V. Blasi L, et al. Among authors: verderame f. Ecancermedicalscience. 2020 May 15;14:1046. doi: 10.3332/ecancer.2020.1046. eCollection 2020. Ecancermedicalscience. 2020. PMID: 32565899 Free PMC article.
61 results